Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes

Minerva Medica

Volumn 102, Issue 6, 2011, Pages 461-468

  Alatab, S ^a   Maghbooli, Z ^a   Hossein Nezhad, Arash ^a   Khosrofar, M ^a   Mokhtari, F ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Multiple sclerosis; Tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; TURBIDIMETRY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANK LIGAND; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84857603023     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Niepel GG, Constantinescu CS. Etiology and pathogenesis of multiple sclerosis. Hospital Pharmacist 2003;10:13-6.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
4. Filippi M. Predictive value of MRI findings in multiple sclerosis. Lancet Neurol 2002;1:9. (Pubitemid 37159191)
5. Kornek B, Lassmann H. Neuropathology of multiple sclerosis - new concepts. Brain Res Bull 2003;61:321-6. (Pubitemid 36952478)
6. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003;23:133-46.
7. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. Journal of Neuropathology & Experimental Neurology 2003;62:723-32. (Pubitemid 36870458)
8. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-12. (Pubitemid 41552953)
9. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH et al. Diagnostic criteria for primary progressive multiple sclerosis:a position paper. Ann Neurol 2000;47:831-5. (Pubitemid 30390209)
10. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006;212:203-16. (Pubitemid 44116710)
11. Sakaguchi S. Naturally arising FOXP3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52. (Pubitemid 41716771)
12. + T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol 2005;175:7135-42.
13. Uraushihara K, Kanai T, Ko K, Totsuka T, Makita S, Iiyama R et al. Regulation of murine inflammatory bowel disease by CD25 and CD25- CD4 glucocorticoid-induced TNF receptor family-related gene regulatory T cells. J Immunol 2003,171:708-16. (Pubitemid 36871380)
14. Torgerson TR. Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol 2006;28:63-76. (Pubitemid 44267960)
15. + regulatory T cells. Nat Immunol 2003;4:330-6.
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science 2003;299:1057-61. (Pubitemid 36222930)
17. + regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006;83:1432-46.
18. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
19. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1643-56.
20. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-7.
21. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK et al. Decreased FOXP3 levels in multiple sclerosis patients. J. of Neuroscience Research. 2005; 81: 45-52 (Pubitemid 41139109)
22. Soilu-Hänninen M, Koskinen JO, Laaksonen M, Hänninen A, Lilius EM, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 2005;65:153-5. (Pubitemid 40967796)
23. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002;46:1744-53. (Pubitemid 34774505)
24. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P et al. The RANKI/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005;54:479-87. (Pubitemid 40395499)
25. Nitta T, Ohigashi I, Nakagawa Y, Takahama Y. Cytokine crosstalk for thymic medulla formation. Curr Opin Immunol 2011;23:190-7.
26. Totsuka T, Kanai T, Nemoto Y, Tomita T, Okamoto R, Tsuchiya K et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. J Immunol 2009;182:6079-87.
27. Ernst CW, Lee JE, Nakanishi T, Karimbux NY, Rezende TM, Stashenko P et al. Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kappaB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease. Clin Exp Immunol 2007;148:271-80. (Pubitemid 46587581)
28. Selmaj K, Raine CS, Cannella B, Brosnan CF, Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-54.
29. Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M et al. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res 2010;1333:64-71.